TD Cowen analyst Joseph Thome has maintained their bullish stance on MCRB stock, giving a Buy rating on March 3.
Joseph Thome’s rating is based on several strategic developments and financial metrics of Seres Therapeutics. The company reported a pro forma cash balance of $81 million, which, along with proceeds from the Vowst sale, is expected to sustain operations into the first quarter of 2026. This financial stability is a positive indicator for potential investors.
Additionally, Seres Therapeutics received encouraging feedback from the FDA regarding the trial design for their lead candidate, SER-155, aimed at infection protection. The FDA’s support for a Phase II trial with a primary endpoint focused on reducing bloodstream infections is a significant step forward. The company also reported promising topline data from a Phase Ib study, showing a 77% relative risk reduction in infections, which further strengthens the case for SER-155’s efficacy. These factors combined suggest a strong potential for growth and success, justifying the Buy rating.
Thome covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, PTC Therapeutics, and uniQure. According to TipRanks, Thome has an average return of 2.0% and a 37.89% success rate on recommended stocks.
In another report released on March 3, Canaccord Genuity also maintained a Buy rating on the stock with a $10.00 price target.